uPAR放射性核素靶向显像研究进展

Research progress of uPAR-targeted nuclear imaging

尿激酶型纤溶酶原激活物及其特异性受体（uPA／uPAR）系统是肿瘤侵袭、转移和血管生成的核心环节之一，且与肿瘤的不良预后密切相关。检测肿瘤组织中uPA／uPAR表达水平及其随病情的变化情况，对于肿瘤预后判断、治疗方案的选择与疗效评价意义重大。放射性核素分子靶向显像方法在靶向受体表达水平测定上具有独特的优势，近来年医学研究者使用多种放射性核素标记uPAR的特异性配体进行了动物显像研究，并于2015年首次用于人体显像。笔者就近年来uPAR放射性核素靶向显像的研究进展作一综述。

Urokinase plasminogen activator （uPA） and urokinase plasminogen activator receptor （uPAR） system play an important role in the process of cancer invasion, metastasis and angiogenesiss, and it is closely associated with poor prognosis of tumors. Evaluate of uPAR expression level in the tumor cell is very significant for cancer prognosis, selection and assement the therapy. Molecular targeted nuclear imaging has unique advantage in testing receptor expression, several research group labeled uPAR specially ligands with different radionuclides for imaging uPAR. The first human uPAR imaging has taken in 2015. This article reviewed the research progress of uPAR-targeted molecular nuclear imaging in recent years.